ASD3MAP: Amorphous Solid Dispersion Digital Design and Manufacturing Platform for rapid and resource-efficient development of bioavailable medicines

ASD3MAP：非晶固体分散体数字设计和制造平台，用于快速、资源高效地开发生物可利用药物

• 批准号: 10078996
• 金额: $ 45.52万
• 依托单位: MESOX LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10078996
• 关键词: ASD3MAP; Amorphous; Solid; Dispersion; Digital

_**ASD3MAP: Amorphous Solid Dispersion Digital Design and Manufacturing Platform for rapid and resource-efficient development of bioavailable medicines.**_MESOX Ltd (Lead), in collaboration with Aston University (Partner), propose an 18-month project focussing on the refinement of the Consortium's molecular dynamics models through the integration of at market material science and simulation tools to deliver an advanced in-silico formulation development platform for amorphous solid dispersions (ASDs). Furthermore, we will integrate the generated modelling data with thermodynamics and novel computational fluid dynamics (CFD) models to predict the impact of cGMP manufacturing scale-up on the formulation.

_**ASD3MAP：非晶固体分散体数字设计和制造平台，用于快速、资源高效地开发生物可利用药物。**_MESOX Ltd（牵头）与阿斯顿大学（合作伙伴）合作，提出了一个为期 18 个月的项目，重点关注通过整合市场材料科学和模拟工具来完善联盟的分子动力学模型，为无定形固体分散体（ASD）提供先进的计算机配方开发平台。此外，我们将生成的建模数据与热力学和新颖的计算流体动力学 (CFD) 模型相结合，以预测 cGMP 生产规模扩大对配方的影响。